Krka, d. d.
KRK
Rang in aandelen
#2157
Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved... Krka, d. d. is a leading generic pharmaceutical enterprise primarily involved in the research, production, promotion, and sale of various pharmaceutical goods. Its market presence spans Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and numerous other international territories. The company's offerings are categorized into prescription medications, over-the-counter products, and veterinary health solutions. Its prescription drug pipeline targets a broad spectrum of medical conditions, including cardiovascular disorders, gastrointestinal issues, central nervous system ailments, pain management, anti-infective treatments, conditions affecting blood and blood-forming organs, urological problems, diabetes, and oncology. The array of non-prescription items includes products for oral and throat care, cough and cold remedies, analgesics, nasal preparations, vitamin and mineral supplements, products designed to enhance cerebral and peripheral circulation, digestive aids, and various general healthcare products. Furthermore, Krka supplies animal health products such as anti-infectives, antiparasitics, and other specialized formulations for both livestock and companion animals. Beyond its pharmaceutical operations, the company also provides health resort and tourist services. Krka, d. d. was established in 1954 and has its corporate headquarters in Novo Mesto, Slovenia.
Aandeelprijs
$313.05
Marktkapitalisatie
$9.48B
Verandering (1 dag)
-1.77%
Verandering (1 jaar)
35.37%
Land
SI
Handel Krka, d. d. (KRK)
Categorie
Healthcare
EPS voor Krka, d. d. (KRK)
EPS per June 2026 TTM: $16.04
Volgens de laatste financiële rapporten en de aandelenkoers van Krka, d. d. is de huidige EPS van het bedrijf (TTM) $16.04. Eind 2023 had het bedrijf een EPS van $11.21, een daling ten opzichte van de EPS van 2022 die $12.54 bedroeg.
EPS-geschiedenis van Krka, d. d. van 2010 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $16.04 | 32.86% |
| 2024 | $12.07 | 7.68% |
| 2023 | $11.21 | -10.61% |
| 2022 | $12.54 | 11.16% |
| 2021 | $11.28 | -0.08% |
| 2020 | $11.29 | 30.17% |
| 2019 | $8.67 | 38.23% |
| 2018 | $6.27 | 10.32% |
| 2017 | $5.69 | 61.36% |
| 2016 | $3.52 | -33.21% |
| 2015 | $5.28 | -13.98% |
| 2014 | $6.13 | -14.87% |
| 2013 | $7.21 | 13.81% |
| 2012 | $6.33 | 0.85% |
| 2011 | $6.28 | -7.19% |
| 2010 | $6.77 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -96.53% |
IN
|
